NY AG Says Actavis Can't Suspend Antitrust Injunction

Law360, New York (January 2, 2015, 3:34 PM EST) -- The New York attorney general has urged the Second Circuit to deny Actavis PLC's bid to hit the brakes on an injunction that prevents it from halting sales of immediate-release dementia drug Namenda while the drugmaker pursues an appeal in the antitrust case, saying patients would be irreparably harmed.

On Tuesday, New York Attorney General Eric T. Schneiderman filed an opposition to a motion filed a day earlier by Actavis and its New York-based subsidiary Forest Laboratories LLC for an emergency stay of a preliminary injunction issued last month by U.S. District Judge Robert W. Sweet. The injunction blocked the drug...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!